← Back to patent-cliff list
Paclitaxel trevatide
Tier C — Watch / tradePaclitaxel trevatide
Angiochem Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：Tubulin, BCL2
Indications (approved)：脑膜癌病, Brain metastases, Breast cancer, Metastatic cancer, Non-small cell lung cancer, Lung cancer, Glioma, Glioblastoma
Regional status
US
Discontinued
2011-10-01
EU
-
China
Phase III
2022-08-12
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Paclitaxel trevatide?
Approved indications include: 脑膜癌病, Brain metastases, Breast cancer, Metastatic cancer, Non-small cell lung cancer, Lung cancer, Glioma, Glioblastoma.
When does the Paclitaxel trevatide patent expire?
No public expiry year is available for Paclitaxel trevatide yet; this page updates once verified.
How do I get a quote for Paclitaxel trevatide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05